OmegaD — Competitive Intelligence Brief

OmegaD (OmegaD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-lowering agent. Area: Cardiovascular.

phase 3 Lipid-lowering agent HMG-CoA reductase Cardiovascular Small molecule

Target snapshot

OmegaD (OmegaD) — OmegaD LLC. OmegaD is a small molecule that modulates the activity of a specific enzyme involved in lipid metabolism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OmegaD TARGET	OmegaD	OmegaD LLC	phase 3	Lipid-lowering agent	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
simvastatin and ezetimibe	simvastatin and ezetimibe	UMC Utrecht	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase and NPC1L1 transporter
Ezetimibe and Simvastatin	Ezetimibe and Simvastatin	University of Texas Southwestern Medical Center	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2037-06-07 — Lipitor · 11654106 · US
• 2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Lipid-lowering agent class)

1. Anja Bisgaard Pinborg · 1 drug in this class
2. OmegaD LLC · 1 drug in this class
3. Sanofi · 1 drug in this class